What is next when the first blood pressure-lowering drug is not sufficient?

References

• Fuchs FD. Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure. Expert Rev. Cardiovasc. Ther.2(5), 771–775 (2004).
   PubMedGoogle Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA289, 2534–2544 (2003).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet351, 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents: effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA202, 1028–1034 (1967).
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM et al; for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA290, 2805–2816 (2003).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet366, 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension–European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens.21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Fuchs FD, Gus M, Ribeiro JP. ASCOT-BPLA. Lancet367, 205 (2006).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet366, 1545–1553 (2005).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med.342, 905–912 (2000).
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension48, 219–224 (2006).
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Psaty B, Greenland P et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA292, 2849–2859 (2004).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. J. Hypertens.21, 1055–1076 (2003).
   PubMed Web of Science ®Google Scholar
• Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol. Assess.7, 1–94 (2003).
   Google Scholar
• Materson BJ, Reda DJ, Cushman WC, Henderson WG. Results of combination anti-hypertensive therapy after failure of each of the components. J. Hypertens.9, 791–796 (1995).
   Web of Science ®Google Scholar
• Blumenfeld JD. JNC-7 versus renin-based strategies for optimal antihypertensive drug treatment. Another look at the evidence. Am. J. Hypertens.17, 1002–1004 (2004).
   PubMed Web of Science ®Google Scholar
• Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimization of antihypertensive treatment by crossover rotation of four major classes. Lancet353, 2008–2013 (1999).
   PubMed Web of Science ®Google Scholar
• Gueyffier F. Antihypertensive treatment (letter). Lancet354, 1028 (1999).
   PubMed Web of Science ®Google Scholar
• Girvin BG, Johnston GD. Comparison of the effects of a 7-day period of non-compliance on blood pressure control using three different antihypertensive agents. J. Hypertens.22, 1409–1414 (2004).
   PubMed Web of Science ®Google Scholar
• Laragh J. Laragh’s lessons in pathophysiology and clinical pearls for treating hypertension. Lesson XVI: how to choose the correct drug treatment for each hypertensive patient using a plasma renin-based method and the volume-vasoconstriction analysis. Am. J. Hypertens.14, 491–503 (2001).
   PubMed Web of Science ®Google Scholar
• British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart91(Suppl. 5), v1–v52 (2005).
   PubMed Web of Science ®Google Scholar
• Neaton JD, Grimm RH Jr, Prineas RJ et al. Treatment Of Mild Hypertension Study (TOMHS): final results. JAMA270, 713–710 (1993).
   PubMed Web of Science ®Google Scholar
• Phillipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorotiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. Br. Med. J.315, 154–159 (1997).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al; Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension42, 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• The National Heart, Lung, and Blood Institute Working Group on future directions in hypertension treatment trials. Major clinical trials of hypertension: what should be done next? Hypertension46, 1–6 (2005).
   PubMed Web of Science ®Google Scholar
• National High Blood Pressure Education Program. Report to the hypertension information and education committee. Task Force I. Database. Recommendations for a National High Blood Pressure Program Database for Effective Antihypertensive Therapy. DHEW Publication No (NIH) 75–593 (1973).
   Google Scholar
• Marre M, Puig JG, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with Type 2 diabetes: the NESTOR Study. J. Hypertens.22, 1613–1622 (2004).
   PubMed Web of Science ®Google Scholar
• Rahman M, Pressel S, Davis BR et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.165, 936–946 (2005).
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet366, 2026–2033 (2005).
   PubMed Web of Science ®Google Scholar